Enlightify flagged by NYSE for sub-$1 share price
Rhea-AI Filing Summary
Enlightify Inc. received notice from the New York Stock Exchange that the 30‑trading‑day average closing price of its common stock fell below $1.00 per share, which is the minimum average share price required for continued listing under NYSE Rule 802.01C. This places the company out of compliance with one of the NYSE’s continued listing standards.
The company informed the NYSE by letter dated September 9, 2025 of its intent to cure this share price deficiency so it can regain compliance with the listing requirement. Enlightify’s common stock continues to trade on the NYSE under the symbol ENFY while it works to address the issue.
Positive
- None.
Negative
- NYSE price-based noncompliance: Enlightify Inc. is out of compliance with the NYSE’s $1.00 minimum 30‑day average share price requirement for continued listing under Rule 802.01C.
Insights
Enlightify faces NYSE minimum price noncompliance but plans to cure it.
Enlightify Inc. has been notified that its 30‑day average closing price fell below $1.00 per share, triggering noncompliance with NYSE Rule 802.01C. This rule requires listed common stocks to maintain at least a $1.00 average closing price over 30 trading days to remain in good standing.
The company has told the NYSE, via a September 9, 2025 letter, that it intends to cure this share price deficiency. Common cure approaches in such situations can include operational improvements or corporate actions, but specific measures are not described in the excerpt. Actual outcomes will depend on whether the stock price recovers sufficiently to satisfy the NYSE’s continued listing standard.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What NYSE issue did Enlightify Inc. (ENFY) disclose?
What is the NYSE listing standard Enlightify (ENFY) failed to meet?
How is Enlightify Inc. responding to the NYSE notice?
Is Enlightify Inc. still listed on the NYSE after this notice?
Does the 8-K mention any specific actions Enlightify (ENFY) will take to cure the deficiency?
AI-generated analysis. How Rhea-AI works. Not financial advice.